Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs ResMed Inc. — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.5× Norwegian Cruise Line Holdings Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and ResMed Inc. for 51 Days on average.
| NCLH | RMD | |
|---|---|---|
Market Cap | $7.11B | $31.89B |
Volume | 22,683,268 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $275.96 |
52-Week Low | $14.12 | $182.82 |
Typical Hold Time | 68 Days | 51 Days |
Enterprise Value | $21.93B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company shows strong profitability with a 7.49% net income margin and attractive valuation metrics, including a P/E of 9.39. Recent news highlights management's focus on booking strategies and debt management, with a $950 million senior notes offering priced in September 2026. Analyst consensus is positive, with a $20.86 price target implying significant upside from current levels.
The outlook for NCLH is cautiously optimistic, supported by earnings strength and analyst buy ratings, but risks include high debt levels and yield pressure. Investment opportunity lies in valuation discount and operational improvements, though investors must monitor competitive dynamics and macroeconomic sensitivity. The stock's trajectory hinges on sustained demand and effective capital allocation.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
